Type 2 Diabetes

SAN DIEGO — Silva A. Arslanian, MD, wishes she could pick the brain of “visionary” Apple founder Steve Jobs — “How did he come up with these ideas? Did he dream them at night?” — and respects billionaire MacKenzie Scott’s mammoth charitable donations.

SAN DIEGO — Genetic data gleaned from an ongoing “-omics” revolution are providing new insights for the prevention and treatment of diabetes that will dramatically change clinical care within the next 10 years, according to a speaker.

Using DNA methylation markers in blood samples may help predict the progression of diabetic kidney disease in patients with type 2 diabetes, recent data suggests.

People with type 2 diabetes who spend more time in glycemic range have lower risks for major adverse cardiovascular events, severe hypoglycemia and microvascular events, according to a post hoc analysis of the DEVOTE trial.

The FDA has approved two forms of empagliflozin as an adjunct to diet and exercise to improve glycemic control in children with type 2 diabetes, according to a press release.

SGLT2 inhibitors reduce risk for CV death and HF events in patients with any or multiple of HF, type 2 diabetes and chronic kidney disease, according to a meta-analysis published in the Journal of the American College of Cardiology.

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, may improve CV risk among patients with type 2 diabetes and kidney disease and those with albuminuria, according to a FIDELITY substudy published in JAMA Cardiology.

Physical activity performed in the afternoon could yield a greater reduction in HbA1c than physical activity during other times in the day, according to an analysis of data from the Look AHEAD trial published in Diabetes Care.

Patients with nonalcoholic steatohepatitis experienced similar mental and work-related impairment as patients with type 2 diabetes mellitus but worse physical status, daily activities impairment and more health care resource use.

The FDA has approved sotagliflozin, a dual SGLT1/SGLT2 inhibitor, for reduction of risk for death, HF hospitalization and urgent HF visits in patients with HF and in those with certain CV risk factors, Lexicon Pharmaceuticals announced.